Table 1 Difference of Hepatitis B patients serum parameters between responders and non-responders at baseline or one-year after PEG-IFN therapy.
From: Baseline value of intrahepatic HBV DNA over cccDNA predicts patient’s response to interferon therapy
Characteristics | Non-responders | P | Responders | P | ||
|---|---|---|---|---|---|---|
Baseline | One-year after IFN | Baseline | One-year after IFN | |||
Age (years) (Mean ± SD) | 26.55 ± 4.76 | 24.50 ± 5.21 | ||||
Gender (Male/Female) | 9/2 | 3/3 | ||||
Therapeutic | Peg-IFN-alpha (n = 11) | Peg-IFN-alpha (n = 6) | ||||
Drug dosage | 180 ug/week | 180 ug/week | ||||
Treatment time (weeks) | 44.7 ± 5.6 | 42 ± 6.57 | ||||
HBV DNA (Log10 IU/mL) | 8.03 ± 0.36 | 5.52 ± 2.15 | 0.018* | 8.28 ± 0.46 | 2.55 ± 1.42 | 0.000* |
HBsAg (Log10 IU/mL) | 4.16 ± 1.11 | 3.61 ± 1.02 | 0.267 | 4.45 ± 0.43 | 1.66 ± 1.18 | 0.002* |
HBeAb (COL) | 4.92 ± 2.48 | 2.72 ± 2.32 | 0.240 | 4.55 ± 1.28 | 0.46 ± 0.53 | 0.001* |
ALT (IU/L) | 119.18 ± 60.43 | 63.73 ± 28.22 | 0.032* | 147.50 ± 99.64 | 47.17 ± 33.86 | 0.005* |
AST (IU/L) | 69.00 ± 38.91 | 44.36 ± 23.87 | 0.439 | 105.83 ± 70.51 | 38.17 ± 17.93 | 0.046* |
ALB (g/L) | 13.30 ± 4.78 | 9.84 ± 3.07 | 0.121 | 12.35 ± 4.79 | 11.78 ± 4.21 | 0.240 |
TBIL (mg/dL) | 43.86 ± 2.76 | 45.44 ± 2.14 | 0.062 | 43.58 ± 2.61 | 45.18 ± 0.90 | 0.816 |
